SNGX - Soligenix, Inc.

...

Available for logged in users only.

The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.

• Soligenix GAAP EPS of -$4.81 misses by $3.68, revenue of $0.9M beats by $0.7M
• Soligenix seeks FDA meeting for review of cancer photodynamic therapy
• Soligenix's stock slumps ~35% as FDA declines to review photodynamic therapy for cancer
• Soligenix to implement 1-for-15 reverse stock split
• Soligenix stock jumps 10% on filing seeking FDA approval of photodynamic therapy for cancer
• Soligenix GAAP EPS of -$0.08 beats by $0.01, revenue of $0.2M in-line
• U.S. FDA awards $2.6M grant for expanded study of Soligenix's HyBryte for skin cancer
• Soligenix announces $2.6M FDA grant to further study blood cancer candidate
• Soligenix GAAP EPS of -$0.06 beats by $0.03, revenue of $0.4M beats by $0.2M
• Soligenix gets agreement from FDA for photodynamic therapy study in kids for lymphoma
• Soligenix, SERB Pharma team up to develop therapy for ricin poisoning
• Soligenix gains 11% on FDA nod to start mid-stage trial for psoriasis candidate
• Soligenix gains on potential U.S. patent win for vaccine platform
• Soligenix GAAP EPS of -$0.10 misses by $0.03, revenue of $0.2M beats by $0.1M
• Soligenix GAAP EPS of -$0.31 misses by $0.01, revenue of $0.8M beats by $0.08M
• Soligenix rises on data from animal study for booster COVID-19 shot
• Soligenix shares non-clinical data to support efficacy of experimental cancer drug
• Soligenix reports 100% protection using a bivalent thermostabilized filovirus vaccine
• Soligenix EPS beats by $0.03, misses on revenue
• Soligenix to advance synthetic hypericin development in psoriasis